14-day Premium Trial Subscription Try For FreeTry Free
$0.0200
+0 (+0%)
At Close: May 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 CALA stock ended at $0.0200. During the day the stock fluctuated 0% from a day low at $0.0200 to a day high of $0.0200.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Calithera Biosciences prices

Date Open High Low Close Volume
Mar 29, 2023 $0.0400 $0.0550 $0.0400 $0.0550 60 546
Mar 28, 2023 $0.0410 $0.0440 $0.0400 $0.0400 32 348
Mar 27, 2023 $0.0410 $0.0500 $0.0410 $0.0500 8 673
Mar 24, 2023 $0.0450 $0.0500 $0.0410 $0.0442 2 848
Mar 23, 2023 $0.0450 $0.0450 $0.0450 $0.0450 261
Mar 22, 2023 $0.0420 $0.0590 $0.0410 $0.0488 40 045
Mar 21, 2023 $0.0510 $0.0600 $0.0510 $0.0600 469
Mar 20, 2023 $0.0420 $0.0500 $0.0420 $0.0500 80 888
Mar 17, 2023 $0.0510 $0.0600 $0.0500 $0.0500 6 831
Mar 16, 2023 $0.0650 $0.0650 $0.0510 $0.0600 52 111
Mar 15, 2023 $0.0650 $0.0650 $0.0510 $0.0510 10 660
Mar 14, 2023 $0.0595 $0.0652 $0.0530 $0.0530 7 090
Mar 13, 2023 $0.0610 $0.0610 $0.0520 $0.0530 10 615
Mar 10, 2023 $0.0600 $0.0600 $0.0500 $0.0520 111 827
Mar 09, 2023 $0.0600 $0.0600 $0.0460 $0.0460 22 703
Mar 08, 2023 $0.0500 $0.0600 $0.0450 $0.0600 31 426
Mar 07, 2023 $0.0600 $0.0600 $0.0500 $0.0500 20 426
Mar 06, 2023 $0.0500 $0.0620 $0.0500 $0.0600 37 252
Mar 03, 2023 $0.0500 $0.0600 $0.0500 $0.0510 33 056
Mar 02, 2023 $0.0600 $0.0642 $0.0500 $0.0500 33 616
Mar 01, 2023 $0.0695 $0.0695 $0.0510 $0.0632 81 174
Feb 28, 2023 $0.0740 $0.0795 $0.0550 $0.0600 205 695
Feb 27, 2023 $0.0757 $0.0845 $0.0740 $0.0740 13 153
Feb 24, 2023 $0.0740 $0.0850 $0.0740 $0.0849 19 596
Feb 23, 2023 $0.0848 $0.0898 $0.0740 $0.0880 75 540
Click to get the best stock tips daily for free!

About Calithera Biosciences

Calithera Biosciences Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginas... CALA Profile

Golden Star

Ticker Date Change Price
CVBF May 01 2.75% $16.75
FTSL May 01 0.282% $46.03
EQC Apr 30 0.694% $18.72
HRB Apr 30 0.635% $47.23
BSCQ Apr 30 0.576% $19.09
BSJP Apr 29 0.306% $22.91
LYG Apr 29 1.56% $2.56
ORA Apr 29 4.68% $64.48
DHT Apr 24 3.10% $11.28
LPLA Apr 19 3.12% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT